Carbon Nanotube-Mediated Delivery of PTEN Variants: In Vitro Antitumor Activity in Breast Cancer Cells.

Rigini M Papi, Konstantinos S Tasioulis, Petros V Kechagioglou, Maria A Papaioannou, Eleftherios G Andriotis, Dimitrios A Kyriakidis

Abstract read

PubMed Full text at PMC Publisher

In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it

0cells of the map it votes in

2citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

Antimicrobial Peptide Papiliocin-Carbon Nanotube Hybrids: Potential Dual-Action Agents for Antimicrobial Activity and Apoptotic Cancer Cell Death.Molecules (Basel, Switzerland) · 2026
Article
Functionalized Carbon Nanotubes: Emerging Nanomaterials for Enhanced Cancer Diagnosis and Imaging.Molecules (Basel, Switzerland) · 2025
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rigini M PapiLaboratory of Biochemistry, Department of Chemistry, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece.ORCID 0000-0002-3183-4724

Konstantinos S TasioulisLaboratory of Biochemistry, Department of Chemistry, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece.ORCID 0000-0002-5018-1837

Petros V KechagioglouLaboratory of Biochemistry, Department of Chemistry, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece.ORCID 0009-0002-1812-6894

Maria A PapaioannouLaboratory of Biological Chemistry, School of Medicine, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece.ORCID 0000-0003-3149-6523

Eleftherios G AndriotisLaboratory of Organic Chemical Technology, Department of Chemistry, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece.ORCID 0000-0002-6812-1779

Dimitrios A KyriakidisLaboratory of Biochemistry, Department of Chemistry, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece.

Funding

"PlantUP" (MIS 5002803) which is implemented under the Action "Reinforcement of the Research and Innovation Infrastructure", funded by the Operational Programme "Competitiveness, Entrepreneurship and Innovation" (NSRF 2014-2020) and co-financed by Greece MIS 5002803

6 · The paper itself

Abstract

Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) is a crucial tumor suppressor protein with frequent mutations and alterations. Although protein therapeutics are already integral to numerous medical fields, their potential remains nascent. This study aimed to investigate the impact of stable, unphosphorylated recombinant human full-length PTEN and its truncated variants, regarding their tumor suppression activity with multiwalled-carbon nanotubes (MW-CNTs) as vehicles for their delivery in breast cancer cells (T-47D, ZR-75-1, and MCF-7). The cloning, overexpression, and purification of PTEN variants were achieved from

Indexed as

ApoptosisBreast NeoplasmsCell ProliferationNanotubes, CarbonPTEN PhosphohydrolaseAntineoplastic AgentsCell Line, TumorFemaleHumansMCF-7 CellsAntineoplastic AgentsNanotubes, CarbonPTEN PhosphohydrolasePTEN protein, humanapoptosisbreast cancer cellscytotoxicityMCF-7multiwalled carbon nanotubesproliferationprotein deliveryPTENT-47DZR-75-1

Identifiers

PMID38930850

DOI10.3390/molecules29122785

PMCPMC11206347

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.